[{"orgOrder":0,"company":"Minovia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"MNV-201","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Minovia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Minovia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Minovia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BioLineRx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ISRAEL","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Motixafortide","moa":"||CXCR-4 receptor","graph1":"Genetic Disease","graph2":"Phase I","graph3":"BioLineRx","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"BioLineRx \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"BioLineRx \/ Inapplicable"},{"orgOrder":0,"company":"BioLineRx","sponsor":"St. Jude Children\u2019s Research Hospital","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"ISRAEL","productType":"Peptide","year":"2024","type":"Agreement","leadProduct":"Motixafortide","moa":"CXCR-4 receptor","graph1":"Genetic Disease","graph2":"Phase I","graph3":"BioLineRx","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"BioLineRx \/ St. Jude Children\u2019s Research Hospital","highestDevelopmentStatusID":"6","companyTruncated":"BioLineRx \/ St. Jude Children\u2019s Research Hospital"},{"orgOrder":0,"company":"BioLineRx","sponsor":"Washington University School of Medicine","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"ISRAEL","productType":"Peptide","year":"2023","type":"Collaboration","leadProduct":"Motixafortide","moa":"||CXCR-4 receptor","graph1":"Genetic Disease","graph2":"Phase I","graph3":"BioLineRx","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"BioLineRx \/ Washington University School of Medicine","highestDevelopmentStatusID":"6","companyTruncated":"BioLineRx \/ Washington University School of Medicine"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Indo Livestock Expo
                          Not Confirmed
                          Indo Livestock Expo
                          Not Confirmed

                          Details : MNV-201, an autologous hematopoietic stem cell product augmented with allogeneic mitochondria. It is being evaluated for the treatment of pearson syndrome.

                          Product Name : MNV-201

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Inapplicable

                          April 03, 2025

                          Lead Product(s) : MNV-201

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          Indo Livestock Expo
                          Not Confirmed
                          Indo Livestock Expo
                          Not Confirmed

                          Details : The agreement aims to evaluate motixafortide for the mobilization of CD34+ hematopoietic stem cells (HSCs) used in the development of gene therapies for patients with sickle cell disease (SCD).

                          Product Name : Aphexda

                          Product Type : Peptide

                          Upfront Cash : Undisclosed

                          May 30, 2024

                          Lead Product(s) : Motixafortide

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Phase I

                          Sponsor : St. Jude Children’s Research Hospital

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          03

                          Indo Livestock Expo
                          Not Confirmed
                          Indo Livestock Expo
                          Not Confirmed

                          Details : The funding will support SpliSense to continue the clinical development of an inhaled antisense oligonucleotide drug SPL84 for treating patients suffering from cystic fibrosis.

                          Product Name : SPL84

                          Product Type : Oligonucleotide

                          Upfront Cash : Undisclosed

                          March 04, 2024

                          Lead Product(s) : SPL84

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Phase I

                          Sponsor : Cystic Fibrosis Foundation

                          Deal Size : $8.5 million

                          Deal Type : Funding

                          blank

                          04

                          Indo Livestock Expo
                          Not Confirmed
                          Indo Livestock Expo
                          Not Confirmed

                          Details : SPL84 is an antisense oligonucleotide product that binds specifically to the mutated CFTR RNA in the targeted sequence. It is being evaluated for the treatment of cystic fibrosis.

                          Product Name : SPL84

                          Product Type : Oligonucleotide

                          Upfront Cash : Inapplicable

                          March 04, 2024

                          Lead Product(s) : SPL84

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          Indo Livestock Expo
                          Not Confirmed
                          Indo Livestock Expo
                          Not Confirmed

                          Details : BioLineRx initiated Phase I clinical trial studies evaluating BL-8040 (motixafortide), CXCR4/SDF-1 inhibitor, as monotherapy and in combination with natalizumab for the treatment of sickle cell disease.

                          Product Name : Aphexda

                          Product Type : Peptide

                          Upfront Cash : Inapplicable

                          December 21, 2023

                          Lead Product(s) : Motixafortide,Natalizumab

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          Indo Livestock Expo
                          Not Confirmed
                          Indo Livestock Expo
                          Not Confirmed

                          Details : SPL84, the Company's lead inhaled anti sense oligonucleotide (ASO) product for the treatment of patients with CF, carrying the 3849+10 kilobase (Kb) C->T splicing mutation in the transmembrane conductance regulator (CFTR) gene.

                          Product Name : SPL84

                          Product Type : Oligonucleotide

                          Upfront Cash : Inapplicable

                          June 09, 2023

                          Lead Product(s) : SPL84

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          Indo Livestock Expo
                          Not Confirmed
                          Indo Livestock Expo
                          Not Confirmed

                          Details : The aim of the collaboration is to advance a Phase 1 clinical trial that will evaluate the safety and feasibility of BL-8040 (motixafortide) to mobilize CD34+ hematopoietic stem cells (HSCs) for gene therapies in sickle cell disease (SCD).

                          Product Name : Aphexda

                          Product Type : Peptide

                          Upfront Cash : Undisclosed

                          June 03, 2023

                          Lead Product(s) : Motixafortide,Natalizumab

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Phase I

                          Sponsor : Washington University School of Medicine

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank